It has previously been shown that high-dose PMX promotes cellular senescence, which contributes to a strong synergistic anti-AD activity when combined with gefitinib, a first-generation EGFR tyrosine kinase inhibitor [60]. The gene discussed is EGFR; the disease is Alzheimer disease.